UniversitätsKlinikum Heidelberg

Publication list for Ion Research at Heidelberg University Hospital

(Status July 2016)

1. Niklas M, Zimmermann F, Schlegel J, Schwager C, Debus J, Jakel O, et al. Registration procedure for spatial correlation of physical energy deposition of particle irradiation and cellular response utilizing cell-fluorescent ion track hybrid detectors. Physics in medicine and biology. 2016;61(17):N441-N60.

2. Mohr A, Chaudhri N, Hassel JC, Federspil PA, Vanoni V, Debus J, et al. Raster-scanned intensity-controlled carbon ion therapy for mucosal melanoma of the paranasal sinus. Head & neck. 2016;38 Suppl 1:E1445-51.

3. Mairani A, Dokic I, Magro G, Tessonnier T, Kamp F, Carlson DJ, et al. Biologically optimized helium ion plans: calculation approach and its in vitro validation. Physics in medicine and biology. 2016;61(11):4283-99.

4. Kurz C, Bauer J, Unholtz D, Richter D, Herfarth K, Debus J, et al. Initial clinical evaluation of PET-based ion beam therapy monitoring under consideration of organ motion. Medical physics. 2016;43(2):975-82.

5. Jensen AD, Poulakis M, Vanoni V, Uhl M, Chaudhri N, Federspil PA, et al. Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? Radiation oncology. 2016;11(1):90.

6. Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, et al. High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016;118(2):272-80.

7. Harrabi SB, Bougatf N, Mohr A, Haberer T, Herfarth K, Combs SE, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2016.

8. Harrabi SB, Adeberg S, Winter M, Haberer T, Debus J, Weber KJ. S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro. Journal of radiation research. 2016;57(2):110-4.

9. Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, et al. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study-The IPI Trial. International journal of radiation oncology, biology, physics. 2016;95(1):435-43.

10. Glowa C, Karger CP, Brons S, Zhao D, Mason RP, Huber PE, et al. Carbon ion radiotherapy decreases the impact of tumor heterogeneity on radiation response in experimental prostate tumors. Cancer letters. 2016;378(2):97-103.

11. Giovannini G, Bohlen T, Cabal G, Bauer J, Tessonnier T, Frey K, et al. Variable RBE in proton therapy: comparison of different model predictions and their influence on clinical-like scenarios. Radiation oncology. 2016;11:68.

12. Gianoli C, Kurz C, Riboldi M, Bauer J, Fontana G, Baroni G, et al. Clinical evaluation of 4D PET motion compensation strategies for treatment verification in ion beam therapy. Physics in medicine and biology. 2016;61(11):4141-55.

13. Dokic I, Mairani A, Niklas M, Zimmermann F, Chaudhri N, Krunic D, et al. Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon-

and oxygen ion beams. Oncotarget. 2016.

14. Chiblak S, Tang Z, Campos B, Gal Z, Unterberg A, Debus J, et al. Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. International journal of radiation oncology, biology, physics. 2016;95(1):112-9.

15. Adeberg S, Harrabi SB, Bougatf N, Bernhardt D, Rieber J, Koerber SA, et al. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2016.

16. Uhl M, Welzel T, Jensen A, Ellerbrock M, Haberer T, Jakel O, et al. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2015;191(7):597-603.

17. Stacchiotti S, Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. The Lancet Oncology. 2015;16(2):e71-83.

18. Simon F, Dittmar JO, Brons S, Orschiedt L, Urbschat S, Weber KJ, et al. Integrin-based meningioma cell migration is promoted by photon but not by carbon-ion irradiation. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2015;191(4):347-55.

19. Saager M, Glowa C, Peschke P, Brons S, Grun R, Scholz M, et al. Split dose carbon ion irradiation of the rat spinal cord: Dependence of the relative biological effectiveness on dose and linear energy transfer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015;117(2):358-63.

20. Rucinski A, Brons S, Richter D, Habl G, Debus J, Bert C, et al. Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel. Radiation oncology. 2015;10:56.

21. Rief H, Chaudhri N, Tonndorf-Martini E, Bruckner T, Rieken S, Bostel T, et al. Intensity-modulated radiotherapy versus proton radiotherapy versus carbon ion radiotherapy for spinal bone metastases: a treatment planning study. Journal of applied clinical medical physics / American College of Medical Physics. 2015;16(6):5618.

22. Rieber JG, Kessel KA, Witt O, Behnisch W, Kulozik AE, Debus J, et al. Treatment tolerance of particle therapy in pediatric patients. Acta oncologica (Stockholm, Sweden). 2015;54(7):1049-55.

23. Prall M, Lehmann HI, Prokesch H, Richter D, Graeff C, Kaderka R, et al. Treatment of arrhythmias by external charged particle beams: a Langendorff feasibility study. Biomedizinische Technik Biomedical engineering. 2015;60(2):147-56.

24. Nicolay NH, Liang Y, Lopez Perez R, Bostel T, Trinh T, Sisombath S, et al. Mesenchymal stem cells are resistant to carbon ion radiotherapy. Oncotarget. 2015;6(4):2076-87.

25. Lehmann HI, Richter D, Prokesch H, Graeff C, Prall M, Simoniello P, et al. Atrioventricular node ablation in Langendorff-perfused porcine hearts using carbon ion particle therapy: methods and an in vivo feasibility investigation for catheter-free ablation of cardiac arrhythmias. Circulation Arrhythmia and electrophysiology. 2015;8(2):429-38.

26. Jensen AD, Uhl M, Chaudhri N, Herfarth KK, Debus J, Roeder F. Carbon Ion irradiation in the treatment of grossly incomplete or unresectable malignant peripheral nerve sheaths tumors: acute toxicity and preliminary outcome. Radiation oncology. 2015;10:109.

27. Jensen AD, Poulakis M, Nikoghosyan AV, Chaudhri N, Uhl M, Munter MW, et al. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and

Oncology. 2015;114(2):182-8.

28. Jensen AD, Nikoghosyan AV, Poulakis M, Hoss A, Haberer T, Jakel O, et al. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival. Cancer. 2015;121(17):3001-9.

29. Jensen AD, Nikoghosyan AV, Lossner K, Haberer T, Jakel O, Munter MW, et al. COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial. International journal of radiation oncology, biology, physics. 2015;93(1):37-46.

30. Hauswald H, Rieken S, Dienemann HC, Thomas M, Kieser M, Debus J, et al. Ion therapy within the trimodal management of superior sulcus tumors: the INKA trial. BMC cancer. 2015;15:192.

31. Habermehl D, Wagner M, Ellerbrock M, Buchler MW, Jakel O, Debus J, et al. Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results. Annals of surgical oncology. 2015;22(6):2068-74.

32. Dreher C, Habermehl D, Ecker S, Brons S, El-Shafie R, Jakel O, et al. Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiation oncology. 2015;10:237.

33. Dokic I, Mairani A, Brons S, Schoell B, Jauch A, Krunic D, et al. High resistance to X-rays and therapeutic carbon ions in glioblastoma cells bearing dysfunctional ATM associates with intrinsic chromosomal instability. International journal of radiation biology. 2015;91(2):157-65.

34. Blattmann C, Oertel S, Thiemann M, Dittmar A, Roth E, Kulozik AE, et al. Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation oncology. 2015;10:146.

35. Uhl M, Welzel T, Oelmann J, Habl G, Hauswald H, Jensen A, et al. Active raster scanning with carbon ions: reirradiation in patients with recurrent skull base chordomas and chondrosarcomas. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2014;190(7):686-91.

36. Uhl M, Mattke M, Welzel T, Roeder F, Oelmann J, Habl G, et al. Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer. 2014;120(21):3410-7.

37. Uhl M, Mattke M, Welzel T, Oelmann J, Habl G, Jensen AD, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer. 2014;120(10):1579-85.

38. Uhl M, Herfarth K, Debus J. Comparing the use of protons and carbon ions for treatment. Cancer journal (Sudbury, Mass). 2014;20(6):433-9.

39. Uhl M, Edler L, Jensen AD, Habl G, Oelmann J, Roder F, et al. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiation oncology. 2014;9:100.

40. Saager M, Glowa C, Peschke P, Brons S, Scholz M, Huber PE, et al. Carbon ion irradiation of the rat spinal cord: dependence of the relative biological effectiveness on linear energy transfer. International journal of radiation oncology, biology, physics. 2014;90(1):63-70.

41. Karger CP, Scholz M, Huber PE, Debus J, Peschke P. Photon and carbon ion irradiation of a rat prostate carcinoma: does a higher fraction number increase the metastatic rate? Radiation research. 2014;181(6):623-8.

42. Habl G, Hatiboglu G, Edler L, Uhl M, Krause S, Roethke M, et al. Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and

carbon ions in a raster scan technique. BMC cancer. 2014;14:202.

43. Habermehl D, Ilicic K, Dehne S, Rieken S, Orschiedt L, Brons S, et al. The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines. PloS one. 2014;9(12):e113591.

44. Gianoli C, Bauer J, Riboldi M, De Bernardi E, Fattori G, Baselli G, et al. Regional MLEM reconstruction strategy for PET-based treatment verification in ion beam radiotherapy. Physics in medicine and biology. 2014;59(22):6979-95.

45. Frey K, Unholtz D, Bauer J, Debus J, Min CH, Bortfeld T, et al. Automation and uncertainty analysis of a method for in-vivo range verification in particle therapy. Physics in medicine and biology. 2014;59(19):5903-19.

46. Bauer J, Sommerer F, Mairani A, Unholtz D, Farook R, Handrack J, et al. Integration and evaluation of automated Monte Carlo simulations in the clinical practice of scanned proton and carbon ion beam therapy. Physics in medicine and biology. 2014;59(16):4635-59.

47. Adeberg S, Baris D, Habermehl D, Rieken S, Brons S, Weber KJ, et al. Evaluation of chemoradiotherapy with carbon ions and the influence of p53 mutational status in the colorectal carcinoma cell line HCT 116. Tumori. 2014;100(6):675-84.

48. Schlaich F, Brons S, Haberer T, Debus J, Combs SE, Weber KJ. Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro. Radiation oncology. 2013;8:260.

49. Rucinski A, Bauer J, Campbell P, Brons S, Unholtz D, Habl G, et al. Preclinical investigations towards the first spacer gel application in prostate cancer treatment during particle therapy at HIT. Radiation oncology. 2013;8:134.

50. Pignalosa D, Lee R, Hartel C, Sommer S, Nikoghosyan A, Debus J, et al. Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;109(2):256-61.

51. Niklas M, Abdollahi A, Akselrod MS, Debus J, Jakel O, Greilich S. Subcellular spatial correlation of particle traversal and biological response in clinical ion beams. International journal of radiation oncology, biology, physics. 2013;87(5):1141-7.

52. Karger CP, Peschke P, Scholz M, Huber PE, Debus J. Relative biological effectiveness of carbon ions in a rat prostate carcinoma in vivo: comparison of 1, 2, and 6 fractions. International journal of radiation oncology, biology, physics. 2013;86(3):450-5.

53. Helmbrecht S, Enghardt W, Parodi K, Didinger B, Debus J, Kunath D, et al. Analysis of metabolic washout of positron emitters produced during carbon ion head and neck radiotherapy. Medical physics. 2013;40(9):091918.

54. Habermehl D, Henkner K, Ecker S, Jakel O, Debus J, Combs SE. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. Journal of radiation research. 2013;54 Suppl 1:i61-8.

55. Habermehl D, Debus J, Ganten T, Ganten MK, Bauer J, Brecht IC, et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiation oncology. 2013;8:59.

56. El Shafie RA, Habermehl D, Rieken S, Mairani A, Orschiedt L, Brons S, et al. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. Journal of radiation research. 2013;54 Suppl 1:i113-9.

57. Combs SE, Kessel K, Habermehl D, Haberer T, Jakel O, Debus J. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta oncologica (Stockholm, Sweden). 2013;52(7):1504-9.

58. Combs SE, Djosanjh M, Potter R, Orrechia R, Haberer T, Durante M, et al. Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. Journal of radiation research. 2013;54 Suppl 1:i6-12.

59. Combs SE, Debus J. Treatment with heavy charged particles: systematic review of clinical data and current clinical (comparative) trials. Acta oncologica (Stockholm, Sweden). 2013;52(7):1272-86.

60. Combs SE, Bruckner T, Mizoe JE, Kamada T, Tsujii H, Kieser M, et al. Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;108(1):132-5.

61. Carozzo S, Schardt D, Narici L, Combs SE, Debus J, Sannita WG. Electrophysiological monitoring in patients with tumors of the skull base treated by carbon-12 radiation therapy. International journal of radiation oncology, biology, physics. 2013;85(4):978-83.

62. Bauer J, Unholtz D, Sommerer F, Kurz C, Haberer T, Herfarth K, et al. Implementation and initial clinical experience of offline PET/CT-based verification of scanned carbon ion treatment. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;107(2):218-26.

63. Sharungbam GD, Schwager C, Chiblak S, Brons S, Hlatky L, Haberer T, et al. Identification of stable endogenous control genes for transcriptional profiling of photon, proton and carbon-ion irradiated cells. Radiation oncology. 2012;7:70.

64. Rieken S, Habermehl D, Wuerth L, Brons S, Mohr A, Lindel K, et al. Carbon ion irradiation inhibits glioma cell migration through downregulation of integrin expression. International journal of radiation oncology, biology, physics. 2012;83(1):394-9.

65. Rieken S, Habermehl D, Haberer T, Jaekel O, Debus J, Combs SE. Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts. Radiation oncology. 2012;7:41.

66. Parodi K, Mairani A, Brons S, Hasch BG, Sommerer F, Naumann J, et al. Monte Carlo simulations to support start-up and treatment planning of scanned proton and carbon ion therapy at a synchrotron-based facility. Physics in medicine and biology. 2012;57(12):3759-84.

67. Kosaki K, Ecker S, Habermehl D, Rieken S, Jakel O, Herfarth K, et al. Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiation oncology. 2012;7:44.

68. Kessel KA, Bougatf N, Bohn C, Habermehl D, Oetzel D, Bendl R, et al. Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. Radiation oncology. 2012;7:115.

69. Jensen AD, Winter M, Kuhn SP, Debus J, Nairz O, Munter MW. Robotic-based carbon ion therapy and patient positioning in 6 degrees of freedom: setup accuracy of two standard immobilization devices used in carbon ion therapy and IMRT. Radiation oncology. 2012;7:51.

70. Jensen AD, Nikoghosyan AV, Lossner K, Herfarth KK, Debus J, Munter MW. IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial. BMC cancer. 2012;12:163.

71. Hauswald H, Rieken S, Ecker S, Kessel KA, Herfarth K, Debus J, et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiation oncology. 2012;7:189.

72. Habermehl D, Blachutzik F, Ecker S, Dittmar JO, Rieken S, Debus J, et al. Early treatment response of a rare papillary tumor of the pineal region after primary proton-beam therapy using the raster-scanning technique at HIT. Tumori. 2012;98(5):122e-5e.

73. Combs SE, Zipp L, Rieken S, Habermehl D, Brons S, Winter M, et al. In vitro evaluation of photon and

carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells. Radiation oncology. 2012;7:9.

74. Combs SE, Kieser M, Habermehl D, Weitz J, Jager D, Fossati P, et al. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC cancer. 2012;12:137.

75. Combs SE, Kessel KA, Herfarth K, Jensen A, Oertel S, Blattmann C, et al. Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. Radiation oncology. 2012;7:170.

76. Combs SE, Bauer J, Unholtz D, Kurz C, Welzel T, Habermehl D, et al. Monitoring of patients treated with particle therapy using positron-emission-tomography (PET): the MIRANDA study. BMC cancer. 2012;12:133.

77. Schlampp I, Karger CP, Jakel O, Scholz M, Didinger B, Nikoghosyan A, et al. Temporal lobe reactions after radiotherapy with carbon ions: incidence and estimation of the relative biological effectiveness by the local effect model. International journal of radiation oncology, biology, physics. 2011;80(3):815-23.

78. Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, Jakel O, et al. Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. International journal of radiation oncology, biology, physics. 2011;81(5):e793-801.

79. Peschke P, Karger CP, Scholz M, Debus J, Huber PE. Relative biological effectiveness of carbon ions for local tumor control of a radioresistant prostate carcinoma in the rat. International journal of radiation oncology, biology, physics. 2011;79(1):239-46.

80. Nikoghosyan AV, Schulz-Ertner D, Herfarth K, Didinger B, Munter MW, Jensen AD, et al. Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer - acute toxicity of 12C for PC. Acta oncologica (Stockholm, Sweden). 2011;50(6):784-90.

81. Jensen AD, Nikoghosyan AV, Windemuth-Kieselbach C, Debus J, Munter MW. Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12). BMC cancer. 2011;11:190.

82. Jensen AD, Nikoghosyan AV, Ecker S, Ellerbrock M, Debus J, Munter MW. Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity. Radiation oncology. 2011;6:30.

83. Jensen AD, Nikoghosyan AV, Ecker S, Ellerbrock M, Debus J, Herfarth KK, et al. Raster-scanned carbon ion therapy for malignant salivary gland tumors: acute toxicity and initial treatment response. Radiation oncology. 2011;6:149.

84. Jensen AD, Nikoghosyan A, Hinke A, Debus J, Munter MW. Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux(R) and particle therapy]. BMC cancer. 2011;11:70.

85. Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Munter MW. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;101(3):383-7.

86. Jensen AD, Munter MW, Debus J. Review of clinical experience with ion beam radiotherapy. The British journal of radiology. 2011;84 Spec No 1:S35-47.

87. Jensen AD, Krauss J, Potthoff K, Desta A, Habl G, Mavtratzas A, et al. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. BMC cancer. 2011;11:182.

88. Jensen AD, Ecker S, Ellerbrock M, Nikoghosyan A, Debus J, Munter MW. Carbon ion therapy for ameloblastic carcinoma. Radiation oncology. 2011;6:13.

89. Combs SE, Kalbe A, Nikoghosyan A, Ackermann B, Jakel O, Haberer T, et al. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;98(1):63-7.

90. Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, et al. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC cancer. 2011;11:67.

91. Nikoghosyan AV, Rauch G, Munter MW, Jensen AD, Combs SE, Kieser M, et al. Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC cancer. 2010;10:606.

92. Nikoghosyan AV, Karapanagiotou-Schenkel I, Munter MW, Jensen AD, Combs SE, Debus J. Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. BMC cancer. 2010;10:607.

93. Munter MW, Wengenroth M, Fehrenbacher G, Schardt D, Nikoghosyan A, Durante M, et al. Heavy ion radiotherapy during pregnancy. Fertility and sterility. 2010;94(6):2329 e5-7.

94. Jensen AD, Nikoghosyan A, Windemuth-Kieselbach C, Debus J, Munter MW. Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC. BMC cancer. 2010;10:546.

95. Combs SE, Kieser M, Rieken S, Habermehl D, Jakel O, Haberer T, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC cancer. 2010;10:478.

96. Combs SE, Jakel O, Haberer T, Debus J. Particle therapy at the Heidelberg Ion Therapy Center (HIT) - Integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;95(1):41-4.

97. Combs SE, Hartmann C, Nikoghosyan A, Jakel O, Karger CP, Haberer T, et al. Carbon ion radiation therapy for high-risk meningiomas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2010;95(1):54-9.

98. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jakel O, et al. Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta oncologica (Stockholm, Sweden). 2010;49(7):1132-40.

99. Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jakel O, et al. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC cancer. 2010;10:615.

100. Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jakel O, et al. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC cancer. 2010;10:533.

101. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC cancer. 2010;10:96.

102. Debus J. Particle therapy--physical, technical and clinical aspects. European journal of cancer (Oxford, England : 1990). 2009;45 Suppl 1:381-2.

103. Combs SE, Nikoghosyan A, Jaekel O, Karger CP, Haberer T, Munter MW, et al. Carbon ion radiotherapy

for pediatric patients and young adults treated for tumors of the skull base. Cancer. 2009;115(6):1348-55.

104. Combs SE, Bohl J, Elsasser T, Weber KJ, Schulz-Ertner D, Debus J, et al. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. International journal of radiation biology. 2009;85(2):126-37.

105. Karger CP, Jakel O, Scholz M, Peschke P, Debus J. What is the clinically relevant relative biologic effectiveness? A warning for fractionated treatments with high linear energy transfer radiation: in regard to Dasu and Toma-DAsu. (Int J Radiat Oncol Biol Phys 2008;70:867-874). International journal of radiation oncology, biology, physics. 2008;70(5):1614; author reply -5.

106. Jakel O, Karger CP, Debus J. The future of heavy ion radiotherapy. Medical physics. 2008;35(12):5653-63.

107. Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs SE, Jakel O, et al. Carbon ion radiotherapy of skull base chondrosarcomas. International journal of radiation oncology, biology, physics. 2007;67(1):171-7.

108. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jakel O, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. International journal of radiation oncology, biology, physics. 2007;68(2):449-57.

109. Jakel O, Schulz-Ertner D, Debus J. Specifying carbon ion doses for radiotherapy: the heidelberg approach. Journal of radiation research. 2007;48 Suppl A:A87-95.

110. Jakel O, Land B, Combs SE, Schulz-Ertner D, Debus J. On the cost-effectiveness of Carbon ion radiation therapy for skull base chordoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2007;83(2):133-8.

111. Karger CP, Peschke P, Sanchez-Brandelik R, Scholz M, Debus J. Radiation tolerance of the rat spinal cord after 6 and 18 fractions of photons and carbon ions: experimental results and clinical implications. International journal of radiation oncology, biology, physics. 2006;66(5):1488-97.

112. Combs SE, Schulz-Ertner D, Herfarth KK, Krempien R, Debus J. [Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 2006;77(12):1126-32.

113. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, et al. Results of carbon ion radiotherapy in 152 patients. International journal of radiation oncology, biology, physics. 2004;58(2):631-40.

114. Schulz-Ertner D, Nikoghosyan A, Didinger B, Debus J. Carbon ion radiation therapy for chordomas and low grade chondrosarcomas--current status of the clinical trials at GSI. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73 Suppl 2:S53-6.

115. Jakel O, Kramer M, Schulz-Ertner D, Heeg P, Karger CP, Didinger B, et al. Treatment planning for carbon ion radiotherapy in Germany: review of clinical trials and treatment planning studies. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73 Suppl 2:S86-91.

116. Haberer T, Debus J, Eickhoff H, Jakel O, Schulz-Ertner D, Weber U. The Heidelberg Ion Therapy Center. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73 Suppl 2:S186-90.

117. Auberger T, Debus J, Gerard JP, Orecchia R, Potter R, Remillieux J, et al. Hadrontherapy with carbon12: radiotherapy of the near future. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2004;73 Suppl 2:i-ii.

118. Weyrather WK, Debus J. Particle beams for cancer therapy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2003;15(1):S23-8.

119. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, et al. Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2003;179(9):598-605.

120. Schulz-Ertner D, Nikoghosyan A, Jakel O, Haberer T, Kraft G, Scholz M, et al. Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. International journal of radiation oncology, biology, physics. 2003;56(2):391-8.

121. Schulz-Ertner D, Nikoghosyan A, Didinger B, Karger CP, Jakel O, Wannenmacher M, et al. Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Physics in medicine and biology. 2003;48(16):2617-31.

122. Schulz-Ertner D, Didinger B, Nikoghosyan A, Jakel O, Zuna I, Wannenmacher M, et al. Optimization of radiation therapy for locally advanced adenoid cystic carcinomas with infiltration of the skull base using photon intensity-modulated radiation therapy (IMRT) and a carbon ion boost. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2003;179(5):345-51.

123. Jakel O, Schulz-Ertner D, Karger CP, Nikoghosyan A, Debus J. Heavy ion therapy: status and perspectives. Technology in cancer research & treatment. 2003;2(5):377-87.

124. Debus J, Scholz M, Haberer T, Peschke P, Jakel O, Karger CP, et al. Radiation tolerance of the rat spinal cord after single and split doses of photons and carbon ions. Radiation research. 2003;160(5):536-42.

125. Schulz-Ertner D, Haberer T, Scholz M, Thilmann C, Wenz F, Jakel O, et al. Acute radiation-induced toxicity of heavy ion radiotherapy delivered with intensity modulated pencil beam scanning in patients with base of skull tumors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2002;64(2):189-95.

126. Schulz-Ertner D, Haberer T, Jakel O, Thilmann C, Kramer M, Enghardt W, et al. Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. International journal of radiation oncology, biology, physics. 2002;53(1):36-42.

127. Karger CP, Debus J, Peschke P, Munter MW, Heiland S, Hartmann GH. Dose-response curves for late functional changes in the normal rat brain after single carbon-on doses evaluated by magnetic resonance imaging: influence of follow-up time and calculation of relative biological effectiveness. Radiation research. 2002;158(5):545-55.

128. Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2001;59(2):161-7.

129. Jakel O, Debus J. Selection of beam angles for radiotherapy of skull base tumours using charged particles. Physics in medicine and biology. 2000;45(5):1229-41.

130. Jakel O, Debus J, Kramer M, Scholz M, Kraft G. Treatment planning for light ions: how to take into account relative biological effectiveness (RBE). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 1999;175 Suppl 2:12-4.

131. Enghardt W, Debus J, Haberer T, Hasch BG, Hinz R, Jakel O, et al. The application of PET to quality assurance of heavy-ion tumor therapy. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 1999;175 Suppl 2:33-6.

132. Eickhoff H, Haberer T, Kraft G, Krause U, Richter M, Steiner R, et al. The GSI Cancer Therapy Project. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 1999;175 Suppl 2:21-4.

133. Debus J, Engenhart-Cabillic R, Kraft G, Wannenmacher M. The role of high-LET radiotherapy compared

to conformal photon radiotherapy in adenoid cystic carcinoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 1999;175 Suppl 2:63-5.

134. Debus J, Jackel O, Kraft G, Wannenmacher M. Is there a role for heavy ion beam therapy? Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 1998;150:170-82.